Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2; Delivery Systems

Treatments: Device: NovoPen® 4

Study type: Observational

Funder types: Industry

Identifiers

NCT00806858

MS236-3663

Details and patient eligibility

About

This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using NovoPen® 4 under normal clinical practice conditions.

Enrollment: 526 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any subject with Type 1 or Type 2 diabetes and accepting to use NovoPen® 4. The selection will be at the discretion of the individual physician.
• A study specific signed informed consent must be signed by each subject before any study-related activities or information is collected, if required by local regulations

Exclusion criteria

• Subjects who are unlikely to comply with the protocol, e.g., unwillingness to cooperate, inability to return for the final visit
• Subjects with known or suspected allergy to any insulin or any of its excipients

Trial design

526 participants in 1 patient group

A

Treatment:

Device: NovoPen® 4